- Home
- ETX vs CHRS Comparison
ETX vs CHRS Comparison
Compare ETX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETX
- CHRS
- Stock Information
- Founded
- ETX 2005
- CHRS 2010
- Country
- ETX United States
- CHRS United States
- Employees
- ETX N/A
- CHRS N/A
- Industry
- ETX
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETX
- CHRS Health Care
- Exchange
- ETX NYSE
- CHRS Nasdaq
- Market Cap
- ETX 193.7M
- CHRS 191.3M
- IPO Year
- ETX N/A
- CHRS 2014
- Fundamental
- Price
- ETX $17.84
- CHRS $1.49
- Analyst Decision
- ETX
- CHRS Strong Buy
- Analyst Count
- ETX 0
- CHRS 4
- Target Price
- ETX N/A
- CHRS $5.38
- AVG Volume (30 Days)
- ETX 32.7K
- CHRS 2.2M
- Earning Date
- ETX 01-01-0001
- CHRS 11-06-2024
- Dividend Yield
- ETX 4.20%
- CHRS N/A
- EPS Growth
- ETX N/A
- CHRS N/A
- EPS
- ETX N/A
- CHRS N/A
- Revenue
- ETX N/A
- CHRS $304,340,000.00
- Revenue This Year
- ETX N/A
- CHRS $2.47
- Revenue Next Year
- ETX N/A
- CHRS N/A
- P/E Ratio
- ETX N/A
- CHRS N/A
- Revenue Growth
- ETX N/A
- CHRS 44.19
- 52 Week Low
- ETX $16.36
- CHRS $0.66
- 52 Week High
- ETX $18.60
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- ETX 41.53
- CHRS 51.20
- Support Level
- ETX $17.76
- CHRS $1.44
- Resistance Level
- ETX $17.85
- CHRS $1.60
- Average True Range (ATR)
- ETX 0.15
- CHRS 0.13
- MACD
- ETX 0.03
- CHRS -0.02
- Stochastic Oscillator
- ETX 73.81
- CHRS 30.95
About ETX EATON VANCE MUNICIPAL INCOME 2028
Eaton Vance Municipal Income 2028 Term Trust is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The fund invests in various sectors such as a bond bank, education, housing, electric utilities, transportation, and others.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.